Life sciences & health care
About life sciences & health care
The industry is tackling many challenges, which are further exacerbated with the current uncertain times.
Declining R&D productivity and loss of exclusivity are definitely top issues on the agenda.
Further, in the context of decreasing government budgets for new drugs and pharmaceuticals, as well as increasing regulatory scrutiny, it becomes even more challenging for Life Sciences companies to get lead times between discovery and new drug launch within acceptable timeframes at acceptable costs. Meanwhile, maximizing revenue from in-line products is becoming increasingly critical.
It is also clear that the current business model is not suitable anymore to handle all of this. In the years to come, huge innovative changes can be expected with new types of partnerships throughout the whole life cycle of a drug.
This website has been developed by Deloitte for all stakeholders in Life Sciences and Health Care to provide a sample of possible solutions to address the challenges ahead and to provide “food for thought” for Life Sciences companies to build this new business model.
